RxDoctor Payments Data

Andres Gavino de la Llana, MD

Internal Medicine · Apple Valley, CANPI 1497802094

Payments from drug & device makers

$1,401in general payments, 2019–2025

Across 40 payments — averaging $35.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Lilly USA, LLC$120
  • AstraZeneca$53
  • Novo Nordisk$25
  • Amgen$23
  • E.r. Squibb & Sons, L.L.C.$22
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$1,401100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,401 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$44,740
Medicare patients
106
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate143$111,802
OzempicSemaglutide86$85,144
EliquisApixaban29$28,150
XareltoRivaroxaban26$24,827
JardianceEmpagliflozin20$20,418
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog45$14,179
Lantus SolostarInsulin Glargine,hum.Rec.Anlog103$12,432
Advair HfaFluticasone Propion/Salmeterol24$8,671
Atrovent HfaIpratropium Bromide17$7,657
Atorvastatin Calcium434$6,560
Insulin Lispro Kwikpen U-100Insulin Lispro43$6,002
Enoxaparin Sodium12$5,954
Breo ElliptaFluticasone/Vilanterol15$5,604
Humalog Kwikpen U-100Insulin Lispro37$5,305
Albuterol Sulfate HfaAlbuterol Sulfate149$5,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$25$87,156106 claims
Johnson & JohnsonXarelto$17$24,82726 claims
Lilly USA, LLCHumalog$120$1,17420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →